ArticleJournal of clinical hypertension (Greenwich, Conn.)2020
What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?
Article in Journal of clinical hypertension (Greenwich, Conn.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Associations of derived inflammatory, lipid, and anthropometric indices with CT-detected pulmonary nodules: a hospital-based cross-sectional study with explainable machine learning.Frontiers in endocrinology · 2026Article
- Review
- Impact of the National Essential Public Health Service Package on Blood Pressure Control in Chinese People With Hypertension: Retrospective Population-Based Longitudinal Study.JMIR public health and surveillance · 2025Article
- Healthy lifestyle and its change attenuated the risk of hypertension among rural population: evidence from a prospective cohort study.Frontiers in public health · 2025Article
- Evaluation of Social Isolation Trajectories and Incident Cardiovascular Disease Among Middle-Aged and Older Adults in China: National Cohort Study.JMIR public health and surveillance · 2023Article
- Persistence of blood pressure phenotypes defined by office and ambulatory measurements in youth of 5 to 15 years of age.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Association Between Hypertension and New-Onset Non-Alcoholic Fatty Liver Disease in Chinese Non-Obese People: A Longitudinal Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- The clinical prediction factors for non-culprit lesion progression in patients with acute ST elevation myocardial infarction after primary percutaneous coronary intervention.BMC cardiovascular disorders · 2022Article
- Associations of multiple chronic disease and depressive symptoms with incident stroke among Chinese middle-aged and elderly adults: a nationwide population-based cohort study.BMC geriatrics · 2022Article
- Association between chronic illness resources and health behaviors in hypertensive stroke patients at 6 months after discharge: a cross-sectional study.Annals of translational medicine · 2022Article
- The Value of Four Anthropometric Indicators for Identifying Left Ventricular Hypertrophy in Chinese Hypertensive Patients.International journal of hypertension · 2022Article
- Clinical Outcome and Medical Cost of Originator and Generic Antihypertensive Drugs: A Population-Based Study in Yinzhou, China.Frontiers in pharmacology · 2022Article
- Association of hypertension and incident diabetes in Chinese adults: a retrospective cohort study using propensity-score matching.BMC endocrine disorders · 2021Article
- Comparison of guidelines for the management of hypertension: Similarities and differences between international and Asian countries; perspectives from HOPE-Asia Network.Journal of clinical hypertension (Greenwich, Conn.) · 2021Review
- Insights on home blood pressure monitoring in Asia: Expert perspectives from 10 countries/regions.Journal of clinical hypertension (Greenwich, Conn.) · 2021Review
- Efficacy of ARB/HCTZ Combination Therapy in Uncontrolled Hypertensive Patients Compared with ARB Monotherapy: A Meta-Analysis.International journal of hypertension · 2021Article
- The HOPE Asia Network activity for "zero" cardiovascular events in Asia: Overview 2020.Journal of clinical hypertension (Greenwich, Conn.) · 2020Review
- What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia?Journal of clinical hypertension (Greenwich, Conn.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 17 institutions in 12 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new Chinese hypertension guideline comprehensively covers almost all major aspects in the management of hypertension. In this new guideline, hypertension remains defined as a systolic/diastolic blood pressure of at least 140/90 mm Hg. For risk assessment, a qualitative approach is used similarly as in previous Chinese guidelines according to the blood pressure level and the presence or absence of other risk factors, target organ damage, cardiovascular complications, and comorbid diseases. The therapeutic target is 140/90 mm Hg in general, and if tolerated, especially in high-risk patients, can be more stringent, that is, 130/80 mm Hg. However, a less stringent target, that is, 150/90 mm Hg, is used in the younger (65-79 years, if tolerated, 140/90 mm Hg) and older elderly (≥80 years). Five classes of antihypertensive drugs, including β-blockers, can be used either in initial monotherapy or combination. The guideline also provided information on the management of hypertension in several special groups of patients and in the presence of secondary causes of hypertension. To implement the guideline recommendations, several nationwide hypertension control initiatives are being undertaken with new technology. The new technological platforms hopefully will help improve the management of hypertension and generate scientific evidence for future hypertension guidelines, including a possible Asian hypertension guideline in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.